154 related articles for article (PubMed ID: 12732886)
1. Prognostic significance of the detection of tumour cells in peripheral blood stem cell collections in stage II and III breast cancer patients treated with high-dose therapy.
Patriarca F; Sacco C; Sperotto A; Geromin A; Damiani D; Fili C; Cerno M; Clochiatti L; Cartei G; Fanin R
Bone Marrow Transplant; 2003 May; 31(9):789-94. PubMed ID: 12732886
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of the immunocytochemical detection of contaminating tumor cells (CTC) in apheresis products of patients with high-risk breast cancer treated with high-dose chemotherapy and stem cell transplantation.
Solano C; Badia B; Lluch A; Marugan I; Benet I; Arbona C; Prosper F; García-Conde J
Bone Marrow Transplant; 2001 Feb; 27(3):287-93. PubMed ID: 11277176
[TBL] [Abstract][Full Text] [Related]
3. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support.
Vredenburgh JJ; Silva O; Broadwater G; Berry D; DeSombre K; Tyer C; Petros WP; Peters WP; Bast RC
Biol Blood Marrow Transplant; 1997 Jun; 3(2):91-7. PubMed ID: 9267669
[TBL] [Abstract][Full Text] [Related]
4. High-dose chemotherapy in patients with breast cancer: evaluation of infusing peripheral blood stem cells containing occult tumor cells.
Weaver CH; Moss T; Schwartzberg LS; Zhen B; West J; Rhinehart S; Campos L; Beeker T; Lautersztain L; Messino M; Buckner CD
Bone Marrow Transplant; 1998 Jun; 21(11):1117-24. PubMed ID: 9645574
[TBL] [Abstract][Full Text] [Related]
5. Micrometastases in apheresis products predict shorter progression-free and overall survival in patients with breast cancer undergoing high-dose chemotherapy (HDCT) and autologous blood stem cell transplantation (ABSCT).
Syme R; Stewart D; Rodriguez-Galvez M; Luider J; Auer Y; Klassen J; Morris D; Brown C; Russell J; Glück S
Bone Marrow Transplant; 2003 Aug; 32(3):307-11. PubMed ID: 12858203
[TBL] [Abstract][Full Text] [Related]
6. Occult tumor cell contamination in patients with stage II/III breast cancer receiving sequential high-dose chemotherapy.
Viret F; Chabannon C; Sainty D; Genre D; Gonçalves A; Arnoulet C; Gravis G; Bertucci F; Houvenaeghel G; Jacquemier J; Bardou VJ; Ladaique P; Braud AC; Maraninchi D; Viens P
Bone Marrow Transplant; 2003 Dec; 32(11):1059-64. PubMed ID: 14625576
[TBL] [Abstract][Full Text] [Related]
7. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse.
Bidard FC; Vincent-Salomon A; Gomme S; Nos C; de Rycke Y; Thiery JP; Sigal-Zafrani B; Mignot L; Sastre-Garau X; Pierga JY;
Clin Cancer Res; 2008 Jun; 14(11):3306-11. PubMed ID: 18519757
[TBL] [Abstract][Full Text] [Related]
8. Occult tumor cells detected in autologous blood stem cell harvests have no impact on 5 year outcomes for breast cancer patients with 4-9 positive nodes treated with adjuvant high-dose therapy and stem cell transplantation.
Reed E; Kessinger A; Murphy B; Tarantolo S; Traystman M; Sharp JG
Bone Marrow Transplant; 2003 Apr; 31(7):571-4. PubMed ID: 12692623
[TBL] [Abstract][Full Text] [Related]
9. Detection of occult cancer cells in peripheral blood and bone marrow by quantitative RT-PCR assay for cytokeratin-7 in breast cancer patients.
Masuda TA; Kataoka A; Ohno S; Murakami S; Mimori K; Utsunomiya T; Inoue H; Tsutsui S; Kinoshita J; Masuda N; Moriyama N; Mori M
Int J Oncol; 2005 Mar; 26(3):721-30. PubMed ID: 15703829
[TBL] [Abstract][Full Text] [Related]
10. Stem cell dose and tumorbiologic parameters as prognostic markers for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous blood stem cell support.
Hensel M; Schneeweiss A; Sinn HP; Egerer G; Kornacker M; Solomayer E; Haas R; Bastert G; Ho AD
Stem Cells; 2002; 20(1):32-40. PubMed ID: 11796920
[TBL] [Abstract][Full Text] [Related]
11. Autologous peripheral blood stem cell transplantation in acute myeloblastic leukaemia and myelodysplastic syndrome patients: evaluation of tumour cell contamination of leukaphereses by cytogenetic and molecular methods.
Testoni N; Lemoli RM; Martinelli G; Carboni C; Pelliconi S; Ottaviani E; Ruggeri D; Rizzi S; Motta MR; Visani G; Tura S
Bone Marrow Transplant; 1998 Dec; 22(11):1065-70. PubMed ID: 9877268
[TBL] [Abstract][Full Text] [Related]
12. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer.
Xenidis N; Ignatiadis M; Apostolaki S; Perraki M; Kalbakis K; Agelaki S; Stathopoulos EN; Chlouverakis G; Lianidou E; Kakolyris S; Georgoulias V; Mavroudis D
J Clin Oncol; 2009 May; 27(13):2177-84. PubMed ID: 19332733
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
[TBL] [Abstract][Full Text] [Related]
14. The clinical significance of tumor cells in bone marrow or apheresis product and the efficacy of CD34+ selection and high-dose chemotherapy in patients with Stage III breast cancer.
Arpaci F; Safali M; Ozet A; Ural AU; Cetin T; Ozturk M; Ataergin S; Kuzhan O; Komurcu S; Ozturk B; Acikel C
J Clin Apher; 2009; 24(5):197-204. PubMed ID: 19816961
[TBL] [Abstract][Full Text] [Related]
15. Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patients.
Schulze R; Schulze M; Wischnik A; Ehnle S; Doukas K; Behr W; Ehret W; Schlimok G
Bone Marrow Transplant; 1997 Jun; 19(12):1223-8. PubMed ID: 9208116
[TBL] [Abstract][Full Text] [Related]
16. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma.
Cai JY; Tang YJ; Jiang LM; Pan C; Chen J; Tang JY
Pediatr Blood Cancer; 2007 Dec; 49(7):952-7. PubMed ID: 17514736
[TBL] [Abstract][Full Text] [Related]
17. Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy.
Kasimir-Bauer S; Mayer S; Bojko P; Borquez D; Neumann R; Seeber S
Clin Cancer Res; 2001 Jun; 7(6):1582-9. PubMed ID: 11410494
[TBL] [Abstract][Full Text] [Related]
18. High-dose therapy and autologous peripheral stem cell transplantation for patients with bone marrow metastases and relapsed lymphoma: an alternative to bone marrow purging.
Kessinger A; Vose JM; Bierman PJ; Armitage JO
Exp Hematol; 1991 Nov; 19(10):1013-6. PubMed ID: 1680733
[TBL] [Abstract][Full Text] [Related]
19. Detection of tumor cells in the bone marrow, peripheral blood, and apheresis products of breast cancer patients using flow cytometry.
Simpson SJ; Vachula M; Kennedy MJ; Kaizer H; Coon JS; Ghalie R; Williams S; Van Epps D
Exp Hematol; 1995 Sep; 23(10):1062-8. PubMed ID: 7544737
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer.
Bozionellou V; Mavroudis D; Perraki M; Papadopoulos S; Apostolaki S; Stathopoulos E; Stathopoulou A; Lianidou E; Georgoulias V
Clin Cancer Res; 2004 Dec; 10(24):8185-94. PubMed ID: 15623593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
